About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker VTRS · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 6, 2026A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and E…
NCT07923045 · Neurotrophic Keratopathy
MR-146
VTRS
Viatris Inc.
Phase 1/2Recruiting18Nov 30, 2027Registry ↗
Nov 3, 2026Dymista in Chinese Adolescents
NCT07597473 · Allergic Rhinitis Due to Allergens
Treatment with 137 µg azelastine hydrochloride and 50 μg of…
VTRS
Viatris Inc.
Phase 4Completed
was active, not recruiting
100Sep 19, 2026Registry ↗
Oct 30, 2026A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From System…
NCT05672576 · Lupus Erythematosus, Systemic
Cenerimod, Placebo
VTRS
Viatris Innovation GmbH
Phase 3Active, not recruiting451Dec 31, 2026Registry ↗
Oct 30, 2026A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Sys…
NCT05648500 · Lupus Erythematosus, Systemic
Cenerimod, Placebo
VTRS
Viatris Innovation GmbH
Phase 3Active, not recruiting470Mar 31, 2027Registry ↗
Oct 27, 2026A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults…
NCT07615868 · Chronic Coronary Syndrome
Selatogrel, Matching placebo
VTRS
Viatris Innovation GmbH
Phase 1Completed20Sep 19, 2026Registry ↗
Oct 27, 2026Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
NCT04957719 · Acute Myocardial Infarction
Selatogrel, Placebo
VTRS
Viatris Innovation GmbH
Phase 3Enrolling by invitation25,000Jul 2027Registry ↗
Oct 15, 2026Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, N…
NCT07813026 · Healthy
Placebo, Oxycodone 20mg
VTRS
Viatris Inc.
Phase 4Recruiting60Jan 31, 2027Registry ↗
Oct 13, 2026Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbear…
NCT06672016 · Female Contraception
Transdermal system containing progestin
VTRS
Mylan Pharmaceuticals Inc
Phase 3Active, not recruiting1,630May 2027Registry ↗
Sep 14, 2026Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cyc…
NCT05139121 · Contraception
MR-100A-01
VTRS
Mylan Technologies Inc.
Phase 3Completed1,320Jan 15, 2025Registry ↗
Sep 11, 2026Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
NCT06475742 · Lupus Erythematosus, Systemic
Cenerimod
VTRS
Viatris Innovation GmbH
Phase 3Enrolling by invitation680Sep 2032Registry ↗
Sep 8, 2026Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sed…
NCT07777965 · Healthy Non-dependent, Recreational Sedative Users
Alprazolam (Xanax), Placebo
VTRS
Viatris Inc.
Phase 4Completed44Aug 31, 2026Registry ↗
Aug 3, 2026Extension Study of MYL-1701P-3001 for Safety and Efficacy
NCT04674800 · Diabetic Macular Edema
MYL-1701P, a proposed biosimilar to Eylea
VTRS
Mylan Pharmaceuticals Inc
Phase 3Completed52Apr 20, 2022Registry ↗
Jul 30, 2026A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on…
NCT07201129 · Nephritis, Lupus, Lupus Erythematosus, Systemic
Cenerimod, Placebo
VTRS
Viatris Innovation GmbH
Phase 3Recruiting300Aug 2029Registry ↗
Jul 29, 2026Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Sy…
NCT03742037 · Systemic Lupus Erythematosus
Cenerimod 0.5 mg, Cenerimod 1 mg
VTRS
Viatris Innovation GmbH
Phase 2Completed427Aug 31, 2021Registry ↗
Jul 29, 2026A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
NCT03487445 · Acute Myocardial Infarction
Selatogrel 8 mg, Selatogrel 16 mg
VTRS
Viatris Innovation GmbH
Phase 2Completed48Nov 10, 2018Registry ↗
Jul 29, 2026A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disea…
NCT03384966 · Stable Coronary Artery Disease
Selatogrel, Placebo
VTRS
Viatris Innovation GmbH
Phase 2Completed346Aug 18, 2018Registry ↗
Jul 29, 2026Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics o…
NCT02472795 · Systemic Lupus Erythematosus
Matching placebo, Cenerimod
VTRS
Viatris Innovation GmbH
Phase 1/2Completed105Jan 23, 2017Registry ↗
Jul 28, 2026A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in A…
NCT07266090 · SLE - Systemic Lupus Erythematosus
cenerimod 4 mg
VTRS
Viatris Pharmaceuticals Co., Ltd.
Phase 2Active, not recruiting15Oct 8, 2027Registry ↗
Jul 14, 2026A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants
NCT07301723 · Healthy Subjects
Cenerimod (oral), 14C-Cenerimod (i.v.)
VTRS
Viatris Innovation GmbH
Phase 1Completed6Mar 18, 2026Registry ↗
Jul 14, 2026A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Ca…
NCT07133191 · Healthy Volunteers
Selatogrel, Matching placebo
VTRS
Viatris Innovation GmbH
Phase 1Completed32Nov 5, 2025Registry ↗
Feb 10, 2026Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy
NCT06215859 · Acute Pain, Post Operative Pain
MR-107A-02, Tramadol
VTRS
Viatris Specialty LLC
Phase 3Completed579Jan 31, 2025Registry ↗
Jan 26, 2026Investigating Ovulation Inhibition for Use as a Contraceptive
NCT07365904 · Contraception
MR-130A-01 contraceptive transdermal patch, containing nore…
VTRS
Mylan Pharmaceuticals Inc
Phase 2Recruiting60Nov 30, 2026Registry ↗
Oct 14, 2025Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy
NCT06215820 · Acute Pain, Post Operative Pain
MR-107A-02, Tramadol
VTRS
Viatris Specialty LLC
Phase 3Completed410Aug 24, 2024Registry ↗
Sep 30, 2025Study to Evaluate the Effectiveness of Legalon®
NCT05051527 · Non-alcoholic Fatty Liver Disease (NAFLD)
Legalon® 140 mg
VTRS
Mylan Inc.
—Completed362Oct 31, 2024Registry ↗
Sep 22, 2025The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics
NCT05004311 · Healthy, Renal Impairment
Cenerimod
VTRS
Viatris Innovation GmbH
Phase 1Completed16Jul 27, 2023Registry ↗
Sep 22, 2025A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of…
NCT04819464 · Healthy, Hepatic Impairment
Cenerimod
VTRS
Viatris Innovation GmbH
Phase 1Completed24Aug 18, 2024Registry ↗
Sep 22, 2025To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Stud…
NCT04255277 · Healthy Subjects
Combined oral contraceptives (COC), Moxifloxacin 400mg
VTRS
Viatris Innovation GmbH
Phase 1Completed97Sep 14, 2021Registry ↗
Sep 22, 2025Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects
NCT04052360 · Healthy Volunteers
Cenerimod, Matching Placebo
VTRS
Viatris Innovation GmbH
Phase 1Completed20Oct 29, 2019Registry ↗
Sep 22, 2025A Study to Evaluate Cenerimod in Healthy Male Subjects
NCT02914223 · Healthy Subjects
Cenerimod
VTRS
Viatris Innovation GmbH
Phase 1Completed6Dec 1, 2016Registry ↗
Sep 22, 2025Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic…
NCT02479204 · Healthy Subjects
ACT-334441 2 mg, ACT-334441 4 mg
VTRS
Viatris Innovation GmbH
Phase 1Terminated10May 1, 2016Registry ↗
Jul 4, 2025The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics
NCT04406896 · Healthy Subjects, Hepatic Impairment
Selatogrel
VTRS
Viatris Innovation GmbH
Phase 1Completed24Oct 23, 2020Registry ↗
Jul 3, 2025A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects
NCT04557280 · Healthy Subjects
Selatogrel, Selatogrel
VTRS
Viatris Innovation GmbH
Phase 1Completed24Dec 19, 2020Registry ↗
Jul 3, 2025A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Health…
NCT03814200 · Healthy Subject
Saline, ACT-246475
VTRS
Viatris Innovation GmbH
Phase 1Completed14Feb 12, 2019Registry ↗
Jul 3, 2025A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects
NCT03593278 · Healthy Subjects
ACT-246475
VTRS
Viatris Innovation GmbH
Phase 1Completed6Aug 5, 2018Registry ↗
Jul 3, 2025A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelo…
NCT03430661 · Healthy
ACT-246475, Clopidogrel
VTRS
Viatris Innovation GmbH
Phase 1Completed77May 20, 2019Registry ↗
Jul 2, 2025A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its…
NCT03173625 · Healthy Subjects
AC-076 for s.c. administration, Placebo
VTRS
Viatris Innovation GmbH
Phase 1Completed72Apr 15, 2017Registry ↗
Nov 29, 2024Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch
NCT06048536 · Contraception
MR-130A-01 Transdermal patch, MR-130A-01 Transdermal patch
VTRS
Mylan Pharmaceuticals Inc
Phase 2Completed168Jan 18, 2024Registry ↗
Nov 1, 2024Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(…
NCT05046795 · COPD
Revefenacin 175 mcg in 3 ML Inhalation Solution, Placebo in…
VTRS
Mylan Pharma UK Ltd.
Phase 3Completed258Jul 26, 2023Registry ↗
Jul 24, 2024Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Partic…
NCT04570436 · Abuse Potential
gabapentin 600 mg, gabapentin 1200 mg
VTRS
Viatris Specialty LLC
Phase 4Completed52Nov 10, 2022Registry ↗
Jun 24, 2024Safety and Efficacy Evaluation of <Dovprela Tablets 200 mg> by Post-marketing Surveillance
NCT06471088 · Dovprela
Dovprela
VTRS
Viatris Inc.
—Unknown100Jun 30, 2026Registry ↗
Apr 24, 2024Food Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg
NCT00650533 · Healthy
Glimepiride Tablets 1 mg, Amaryl® Tablets 1 mg
VTRS
Mylan Pharmaceuticals Inc
Phase 1Completed40Dec 2004Registry ↗
Apr 24, 2024Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets
NCT00650520 · Healthy
BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg, Parlodel® (bromo…
VTRS
Mylan Pharmaceuticals Inc
Phase 1Completed119Jul 2007Registry ↗
Apr 24, 2024Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg
NCT00650481 · Healthy
Oxybutynin Chloride Extended-release Tablets 5 mg, Ditropan…
VTRS
Mylan Pharmaceuticals Inc
Phase 1Completed60Dec 2002Registry ↗
Apr 24, 2024Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg
NCT00650416 · Healthy
Carvedilol Tablets 12.5 mg, Coreg® Tablets 12.5 mg
VTRS
Mylan Pharmaceuticals Inc
Phase 1Completed50Apr 2004Registry ↗
Apr 24, 2024Food Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg
NCT00650403 · Healthy
Paroxetine hydrochloride 40 mg tablet, Paxil® 40 mg Tablet
VTRS
Mylan Pharmaceuticals Inc
Phase 1Completed66Dec 2006Registry ↗
Apr 24, 2024Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg
NCT00650364 · Healthy
Midodrine HCl Tablets 5 mg, ProAmatine® Tablets 5 mg
VTRS
Mylan Pharmaceuticals Inc
Phase 1Completed38Aug 2002Registry ↗
Apr 24, 2024Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg
NCT00650351 · Healthy
Ciprofloxacin Extended-Release Tablets 1000 mg, Cipro® XR T…
VTRS
Mylan Pharmaceuticals Inc
Phase 1Completed35Oct 2005Registry ↗
Apr 24, 2024Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg
NCT00650325 · Healthy
Sertraline Hydrochloride Tablets 100 mg, Zoloft® Tablets 10…
VTRS
Mylan Pharmaceuticals Inc
Phase 1Completed49Dec 2002Registry ↗
Apr 24, 2024Fasting Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg
NCT00650312 · Healthy
Metformin Hydrochloride ER Tablets 500 mg, Glucophage® XR T…
VTRS
Mylan Pharmaceuticals Inc
Phase 1Completed50Oct 2002Registry ↗
Apr 24, 2024Fed Study of Alprazolam Extended-release Tablets 3 mg to Xanax XR® Tablets 3 mg
NCT00650299 · Healthy
Alprazolam Extended-release Tablets 3 mg, Xanax XR® Tablets…
VTRS
Mylan Pharmaceuticals Inc
Phase 1Completed21Aug 2004Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:34 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances